NCT04094298
Use of Extended Release Triamcinolone in the Treatment of Rotator Cuff Disease
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 13 versions: 10 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗
Stopped Trial terminated Sponsor's reason: The primary reasons for early study termination are administrative and funding issues and inability to obtain the investigational product; this lead to insufficient participant enrollment. Show 8 more changesShow less
- Study completion date changed from estimate of Jan 31, 2025 to Oct 9, 2025
- Results posted: Nov 4, 2026
- Start date: Jul 15, 2019 to Aug 27, 2020
- Eligibility criteria expanded, about 12 words
- Final enrollment: 40 participants (planned 65)
- Secondary endpoints revised (4)
- Primary endpoint revised
- Publications: details revised at 5 of 5 entries
- Minor Trial status: Recruiting to Active, Not Recruiting
- Primary completion date changed from estimate of Dec 1, 2024 to Oct 10, 2024
- Study completion date: Dec 1, 2024 to Jan 31, 2025
- Site details revised
- Notable Primary completion date: Dec 1, 2023 to Dec 1, 2024v10
- Minor Primary completion date: Sep 1, 2023 to Dec 1, 2023
- Study completion date: Sep 1, 2024 to Dec 1, 2024
- Minor Site contact updatedv8
Show 4 earlier versionsHide 4 earlier versions
- Notable Primary completion date: Sep 1, 2021 to Sep 1, 2023
- Study completion date: Sep 1, 2022 to Sep 1, 2024
- Collaborators shortened, about 3 words
- Notable Trial status: Suspended to Recruiting
- Site details revised
- Minor Study site revised
- Collaborator revised
- Stopped Trial status: Recruiting to Suspended Sponsor's reason: Institutional roadblocks.
- Site details revised
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Incidence of Adverse Events
Timeframe: 24 weeks
Secondary (4)
Change in Shoulder Pain as Assessed by VAS
Change in Shoulder Function as Assessed by SANE
Change in Shoulder Function as Assessed by VR-12
Change in Shoulder Function as Assessed by ASES
Arms and interventions
Treatment GroupExperimental
Patients receiving the 32-unit injection of FX006.
Drugs: FX006 Injection
Sites
1 site in 1 country
- Northwell Health Orthopedic Institute at Great NeckGreat Neck, New York, United States